TY - JOUR
T1 - HLA-DP mismatch and CMV reactivation increase risk of aGVHD independently in recipients of allogeneic stem cell transplant
AU - Ghobadi, Armin
AU - Milton, Denái R.
AU - Gowda, Lohith
AU - Rondon, Gabriela
AU - Chemaly, Roy F.
AU - Hamdi, Amir
AU - Alousi, Amin
AU - Afrough, Aimaz
AU - Oran, Betul
AU - Ciurea, Stefan
AU - Kebriaei, Partow
AU - Popat, Uday R.
AU - Qazilbash, Muzaffar H.
AU - Shpall, Elizabeth J.
AU - Champlin, Richard E.
AU - Bashir, Qaiser
N1 - Publisher Copyright:
© 2019 Elsevier Masson SAS
PY - 2019/5
Y1 - 2019/5
N2 - HLA-DP mismatched allogeneic hematopoietic stem cell transplantation (allo-HCT) is associated with increased risk of aGVHD and decreased risk of relapse with no effects on overall survival (OS). It has been proposed that CMV-reactivation induces expression of HLA-DP molecules on GVHD target tissues by releasing inflammatory cytokines. We hypothesized that the increased GVHD incidence in HLA-DP mismatched allo-SCTs correlates with recipient CMV serostatus or CMV reactivation. In addition, CMV reactivation is associated with increased risk of GVHD with an unknown mechanism. Here, we analyzed the association between HLA-DPB1 and CMV reactivation on cumulative incidence of aGVHD and relapse as well as OS in 613 patients with AML and MDS who underwent matched related or unrelated allo-HCT at MD Anderson Cancer Center from 2005 to 2011. In multivariable analysis, HLA-DPB1 mismatching was associated with increased risk of aGVHD (hazard ratio (HR): 1.53, P < 0.001) independent of CMV serostatus and CMV reactivation. Additionally, HLA-DPB1 mismatching was associated with decreased risk of relapse and no effect on OS. CMV reactivation increased risks of aGVHD (HR: 5.82, P < 0.001) independent of HLA-DP mismatching with no effect on relapse or OS. In conclusion, our data suggests that HLA-DPB1 mismatching and CMV reactivation increase risk of aGVHD independently.
AB - HLA-DP mismatched allogeneic hematopoietic stem cell transplantation (allo-HCT) is associated with increased risk of aGVHD and decreased risk of relapse with no effects on overall survival (OS). It has been proposed that CMV-reactivation induces expression of HLA-DP molecules on GVHD target tissues by releasing inflammatory cytokines. We hypothesized that the increased GVHD incidence in HLA-DP mismatched allo-SCTs correlates with recipient CMV serostatus or CMV reactivation. In addition, CMV reactivation is associated with increased risk of GVHD with an unknown mechanism. Here, we analyzed the association between HLA-DPB1 and CMV reactivation on cumulative incidence of aGVHD and relapse as well as OS in 613 patients with AML and MDS who underwent matched related or unrelated allo-HCT at MD Anderson Cancer Center from 2005 to 2011. In multivariable analysis, HLA-DPB1 mismatching was associated with increased risk of aGVHD (hazard ratio (HR): 1.53, P < 0.001) independent of CMV serostatus and CMV reactivation. Additionally, HLA-DPB1 mismatching was associated with decreased risk of relapse and no effect on OS. CMV reactivation increased risks of aGVHD (HR: 5.82, P < 0.001) independent of HLA-DP mismatching with no effect on relapse or OS. In conclusion, our data suggests that HLA-DPB1 mismatching and CMV reactivation increase risk of aGVHD independently.
KW - Allogeneic hematopoietic stem cell transplantation
KW - CMV
KW - HLA-DP
UR - http://www.scopus.com/inward/record.url?scp=85060191285&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85060191285&partnerID=8YFLogxK
U2 - 10.1016/j.retram.2019.01.001
DO - 10.1016/j.retram.2019.01.001
M3 - Article
C2 - 30683577
AN - SCOPUS:85060191285
SN - 2452-3186
VL - 67
SP - 51
EP - 55
JO - Current Research in Translational Medicine
JF - Current Research in Translational Medicine
IS - 2
ER -